| Renal Cell Carcinoma |
1 |
1 |
| Biologic Therapy |
0 |
0.95 |
| Cancer |
0 |
0.71 |
| Antineoplastic Drug |
0 |
0.63 |
| Metastasis |
0 |
0.59 |
| Adjuvant Therapy |
0 |
0.99 |
| Tyrosine Kinase Inhibitor |
0 |
0.49 |
| Disease Recurrence |
0 |
0.27 |
| Kidney Cancer |
0 |
0.98 |
| Immunotherapy |
0 |
0.18 |
| Surgery |
0 |
0.18 |
| Clinical Guidelines |
0 |
0.15 |
| Antiretroviral Therapy for HIV Infection |
0 |
0.1 |
| HIV Infection |
0 |
0.1 |
| Biomarker |
0 |
0.09 |
| Blood |
0 |
0.09 |
| California |
0 |
0.09 |
| Clinical Research |
0 |
0.09 |
| Europe |
0 |
0.09 |
| Nucleoside Reverse Transcriptase Inhibitors |
0 |
0.09 |
| Quality of Life |
0 |
0.09 |
| Resection |
0 |
0.09 |
| Tissue |
0 |
0.09 |
| Transplant Evaluation |
0 |
0.09 |
| Tumor |
0 |
0.09 |
| Vascular Endothelial Growth Factor |
0 |
0.09 |